Anavex Life Sciences (AVXL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

Anavex Life Sciences (NASDAQ:AVXL) stock rallied 30% Monday after the company issued its fiscal Q3 earnings report and announced EU regulators had accepted the market application for its Alzheimer's ...

In trading on Monday, shares of Anavex Life Sciences Corp (Symbol: AVXL) touched a new 52-week high of $10.45/share. That's a 221.54% rise, or $7.2 per share from the 52-week low of $3.25 set back on ...

Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's. Find out why AVXL stock is a Sell.

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to take a look at where Anavex Life Sciences Corp. (NASDAQ:AVXL) stands against ...

We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a look at where Anavex Life Sciences Corp. (NASDAQ:AVXL) stands against ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Anavex Life Sciences (AVXL) one of those stocks right now? A ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) on Saturday announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration on clinical decline, ...